Innoviva (INVA) Stock Analysis & Winston Score
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consis
Winston Score: 66/100 — Good
A decent business — some strong pillars, some weaker.
- Quality: Strong (21/30)
- Growth: Strong (14/20)
- Cash Flow: Good (5/10)
- Stability: Exceptional (9/10)
- Valuation: Good (6/10)
- Ownership: Good (8/15)
Key Facts
Price: $21.71
Market Cap: $1.6B
Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ


